Acetylcholinesterase-capped Mesoporous Silica Nanoparticles Controlled by the Presence of Inhibitors.
Two different acetylcholinesterase (AChE)-capped mesoporous silica nanoparticles (MSNs), S1-AChE and S2-AChE, were prepared and characterized. MSNs were loaded with rhodamine B and the external surface was functionalized with either pyridostigmine derivative P1 (to yield solid S1) or neostigmine derivative P2 (to obtain S2). The final capped materials were obtained by coordinating grafted P1 or P2 with AChE's active sites (to give S1-AChE and S2-AChE, respectively). Both materials were able to release rhodamine B in the presence of diisopropylfluorophosphate (DFP) or neostigmine in a concentration-dependent manner via the competitive displacement of AChE through DFP and neostigmine coordination with the AChE's active sites. The responses of S1-AChE and S2-AChE were also tested with other enzyme inhibitors and substrates. These studies suggest that S1-AChE nanoparticles can be used for the selective detection of nerve agent simulant DFP and paraoxon.
Departamento de Química, Universidad Politécnica de Valencia, Camino de Vera s/n, 46022, Valencia, Spain.|Instituto Interuniversitario de Investigación de Reconocimiento MolecularyDesarrollo Tecnológico (IDM), Universitat Politécnica de Valencia, Universitat de Valencia, Spain.|CIBER de Bioingeniería, BiomaterialesyNanomedicina (CIBER-BBN), Spain.
Lluís
L
Pascual
Departamento de Química, Universidad Politécnica de Valencia, Camino de Vera s/n, 46022, Valencia, Spain.|Instituto Interuniversitario de Investigación de Reconocimiento MolecularyDesarrollo Tecnológico (IDM), Universitat Politécnica de Valencia, Universitat de Valencia, Spain.|CIBER de Bioingeniería, BiomaterialesyNanomedicina (CIBER-BBN), Spain.
Sameh
S
El Sayed
Departamento de Química, Universidad Politécnica de Valencia, Camino de Vera s/n, 46022, Valencia, Spain.|Instituto Interuniversitario de Investigación de Reconocimiento MolecularyDesarrollo Tecnológico (IDM), Universitat Politécnica de Valencia, Universitat de Valencia, Spain.|CIBER de Bioingeniería, BiomaterialesyNanomedicina (CIBER-BBN), Spain.
María D
MD
Marcos
Departamento de Química, Universidad Politécnica de Valencia, Camino de Vera s/n, 46022, Valencia, Spain.|Instituto Interuniversitario de Investigación de Reconocimiento MolecularyDesarrollo Tecnológico (IDM), Universitat Politécnica de Valencia, Universitat de Valencia, Spain.|CIBER de Bioingeniería, BiomaterialesyNanomedicina (CIBER-BBN), Spain.
Ramón
R
Martínez-Máñez
Departamento de Química, Universidad Politécnica de Valencia, Camino de Vera s/n, 46022, Valencia, Spain.|Instituto Interuniversitario de Investigación de Reconocimiento MolecularyDesarrollo Tecnológico (IDM), Universitat Politécnica de Valencia, Universitat de Valencia, Spain.|CIBER de Bioingeniería, BiomaterialesyNanomedicina (CIBER-BBN), Spain.
Félix
F
Sancenón
D000110:Acetylcholinesterase / Q000737:chemistry*; D020134:Catalytic Domain; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D007531:Isoflurophate / Q000737:chemistry / Q000494:pharmacology; D053758:Nanoparticles / Q000737:chemistry*; D016062:Porosity; D012235:Rhodamines / Q000737:chemistry; D012822:Silicon Dioxide / Q000737:chemistry*; D013499:Surface Properties
D004791:Enzyme Inhibitors; D012235:Rhodamines; D007531:Isoflurophate; D012822:Silicon Dioxide; D000110:Acetylcholinesterase; C029773:rhodamine B
acetylcholinesterase; enzyme inhibitors; enzyme-capped nanoparticles; neostigmine; nerve agent simulants